Back to News
Market Impact: 0.3
Epicrispr Reports Positive Six-Month Data at The World Muscle Society Meeting Demonstrating Increased Lean Muscle Volume and Muscle Strength in FSHD Patients Treated with EPI-321
Source: Business Wire
Healthcare & Biotech
Epicrispr reported positive six-month data for EPI-321 in patients with FSHD, showing increased lean muscle volume and muscle strength. The headline does not provide the magnitude of the changes or other study details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
More News
- AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
- BTIG reiterates Vaxcyte stock rating on strong VAX-31 trial data
- Why is NeoGenomics stock sliding today?
- Up 57% since June: this AI-picked pharma stock keeps climbing
- These stocks could benefit from a midterm election shake-up, JPMorgan says
- Vaxcyte shares surge on late-stage vaccine trial success